Lyra Therapeutics, Inc. (LYRA)
OTHER OTC:LYRA
Total Valuation
Lyra Therapeutics has a market cap or net worth of $870.23K. The enterprise value is $15.15M.
Market Cap$870.23K
Enterprise Value$15.15M
Share Statistics
Lyra Therapeutics has 1,774,882 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,774,882
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Lyra Therapeutics’s return on equity (ROE) is 2.70 and return on invested capital (ROIC) is -98.75%.
Return on Equity (ROE)2.70
Return on Assets (ROA)-0.80
Return on Invested Capital (ROIC)-98.75%
Return on Capital Employed (ROCE)-1.17
Revenue Per Employee13.27K
Profits Per Employee-963.97K
Employee Count30
Asset Turnover0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lyra Therapeutics is ―. Lyra Therapeutics’s PEG ratio is -0.00138.
PE Ratio―
PS Ratio120.22
PB Ratio-4.46
Price to Fair Value-4.46
Price to FCF-1.65
Price to Operating Cash Flow-0.24
PEG Ratio-0.00138
Income Statement
In the last 12 months, Lyra Therapeutics had revenue of 398.00K and earned -28.92M in profits. Earnings per share was -18.62.
Revenue398.00K
Gross Profit0.00
Operating Income-31.02M
Pretax Income-28.91M
Net Income-28.92M
EBITDA-31.02M
Earnings Per Share (EPS)-18.62
Cash Flow
In the last 12 months, operating cash flow was -28.86M and capital expenditures -116.00K, giving a free cash flow of -28.98M billion.
Operating Cash Flow-28.86M
Free Cash Flow-28.98M
Free Cash Flow per Share-16.33
Dividends & Yields
Lyra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.80
52-Week Price Change-91.25%
50-Day Moving Average1.24
200-Day Moving Average4.92
Relative Strength Index (RSI)27.14
Average Volume (3m)93.63K
Important Dates
Lyra Therapeutics upcoming earnings date is May 12, 2026, After Close (Confirmed).
Last Earnings DateMar 11, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
Lyra Therapeutics as a current ratio of 1.71, with Debt / Equity ratio of -282.35%
Current Ratio1.71
Quick Ratio1.71
Debt to Market Cap0.63
Net Debt to EBITDA-0.46
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lyra Therapeutics has paid -11.00K in taxes.
Income Tax-11.00K
Effective Tax Rate<0.01
Enterprise Valuation
Lyra Therapeutics EV to EBITDA ratio is -2.01, with an EV/FCF ratio of -2.15.
EV to Sales156.31
EV to EBITDA-2.01
EV to Free Cash Flow-2.15
EV to Operating Cash Flow-2.16
Balance Sheet
Lyra Therapeutics has $15.89M in cash and marketable securities with $30.26M in debt, giving a net cash position of -$14.37M billion.
Cash & Marketable Securities$15.89M
Total Debt$30.26M
Net Cash-$14.37M
Net Cash Per Share-$8.09
Tangible Book Value Per Share-$0.69
Margins
Gross margin is 0.00%, with operating margin of -7794.47%, and net profit margin of -7266.08%.
Gross Margin0.00%
Operating Margin-7794.47%
Pretax Margin-7263.32%
Net Profit Margin-7266.08%
EBITDA Margin-7794.47%
EBIT Margin0.00%
Analyst Forecast
The average price target for Lyra Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-59.21%
EPS Growth Forecast68.97%